Description: Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea.
Home Page: www.hanall.co.kr
Daewoong Building
Seoul,
South Korea
Phone:
82 2 550 8800
Officers
| Name | Title |
|---|---|
| Mr. Seung-Kook Park | Pres, CEO & Exec. Director |
| Sung-Soo Jeon | VP |
| Jae-Hwan Kim | VP |
| Mr. Jong-Min Yeo | Exec. Officer |
| Mr. Sung-Joon Choi | Vice-Pres |
| Sean Jeong | Pres, CEO & Director |
| Sung-yon Lim | CFO & Director |
| Nam-Yong Cho | Sr. Exec. Director of Sales & Marketing and Sr. Managing Director |
Exchange: KO
Country: KR
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.2819 |
| Price-to-Sales TTM: | 7.6933 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 302 |